Treatment Options From 5 Experts for Patients With HER2-Positive Early-Stage Breast Cancer

Were you recently diagnosed with HER2-positive early-stage breast cancer? CCO and GRACE have partnered to develop a Treatment Decision Support Tool to help you understand more about your cancer diagnosis and treatment options. Answer these multiple choice questions to see treatment plans from 5 oncology experts.

Share

Program Content

Activities

HER2+ EBC Consultation Checklist
Online Treatment Tool for Patients: Key Information You Need to Know About Your HER2-Positive Early Breast Cancer Diagnosis
PDF
Congratulations: You achieved a completion on 04/09/2022

Released: March 19, 2019

Expires: March 17, 2020

Activities

Expert Insights on HER2+ EBC
Treatment Options From 5 Experts on Neoadjuvant and Adjuvant Therapy for HER2-Positive Early Breast Cancer: An Online Tool
Tool
Congratulations: You achieved a completion on 04/09/2022

Released: March 19, 2019

Expires: March 17, 2020

Faculty

cover img faculity

Frankie Ann Holmes, MD, FACP

Medical Oncologist
US Oncology/Texas Oncology
Houston, Texas

cover img faculity

Sara Hurvitz, MD

Assistant Professor of Medicine
Director, Breast Oncology Program
Division of Hematology-Oncology
Department of Internal Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

cover img faculity

Joyce O’Shaughnessy, MD

Co-Director, Breast Cancer Research
Baylor Charles A. Sammons Cancer Center
Texas Oncology
US Oncology
Dallas, Texas

cover img faculity

Mark D. Pegram, MD

Leonard M. Miller School of Medicine
University of Miami
Miami, Florida

cover img faculity

Denise A. Yardley, MD

Senior Investigator
Breast Cancer Research Program
The Sarah Cannon Research Institute and Tennessee Oncology
Nashville, Tennessee

Provided by

ProCE Banner

Supporters

This activity is supported by an educational grant from

Genentech TEXT Only

Partners

GRACE

ProCE Banner